Novo Nordisk


Zuellig Pharma
Concise Prescribing Info
Adjunct to a reduced-calorie diet & increased physical activity for wt management in adult patients w/ an initial BMI of ≥30 kg/m2 (obese) or ≥27 kg/m2 to <30 kg/m2 (overwt) in the presence of at least 1 wt-related comorbidity eg, dysglycaemia (pre-diabetes or type 2 DM), HTN, dyslipidaemia or obstructive sleep apnoea.
Dosage/Direction for Use
SC Initially 0.6 mg once daily. Should be increased to 3 mg once daily in increments of 0.6 mg w/ at least 1 wk interval. Maintenance: 3 mg.
May be taken with or without food.
Special Precautions
Do not use as a substitute for insulin. Not recommended in patients w/ CHF NYHA class IV; treated w/ other products for wt management; w/ obesity secondary to endocrinological or eating disorders or to treatment w/ medicinal products that may cause wt gain; patients w/ inflammatory bowel disease & diabetic gastroparesis. Discontinue use if pancreatitis is suspected & should not be restarted if acute pancreatitis is confirmed. Higher rate of cholelithiasis & cholecystitis. Patients w/ thyroid disease. Counsel patients regarding potential risk for medullary thyroid carcinoma & thyroid tumours symptoms. Monitor heart rate at regular intervals & inform patients of the symptoms of increased heart rate; discontinue w/ sustained increase in resting heart rate. Potential risk of dehydration in relation to GI side effects. May increase risk of hypoglycaemia in combination w/ a sulfonylurea in patients w/ type 2 DM. Monitor for the emergence or worsening of depression, suicidal thoughts or behaviour &/or any unusual changes in mood or behaviour; discontinue in patients who experience suicidal thoughts or behaviours; avoid in patients w/ history of suicidal attempts or active suicidal ideation. Not for combination use w/ another GLP-1 receptor agonist. Not recommended in patients w/ severe renal impairment (CrCl <30 mL/min) & end-stage renal disease; hepatic impairment. Do not use during pregnancy & lactation. Not recommended for use in childn & adolescent <18 yr. Not recommended in elderly ≥75 yr.
Adverse Reactions
Nausea, vomiting, diarrhoea, constipation. Hypoglycaemia; insomnia; dizziness, dysgeusia; dry mouth, dyspepsia, gastritis, GERD, upper abdominal pain, flatulence, eructation, abdominal distention; cholelithiasis; inj site reactions, asthenia, fatigue; increased lipase & amylase.
Drug Interactions
Frequent monitoring of INR in patients on warfarin or other coumarin derivatives.
MIMS Class
Anti-Obesity Agents / Antidiabetic Agents
ATC Classification
A10BJ02 - liraglutide ; Belongs to the class of glucagon-like peptide-1 (GLP-1) analogues. Used in the treatment of diabetes.
Saxenda soln for inj 6 mg/mL
3 mL x 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Already a member? Sign in